| Name | Title | Contact Details |
|---|
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC).
We`re building partnerships and transforming care. Alternate Solutions Health Network was founded in 1999 by David and Tessie Ganzsarto. We collaborate with health systems in joint venture partnerships to create a post-acute care solution, delivering efficient centralized operations and utilizing a best-in-class software platform. Our company has been dedicated, since the very beginning, to transforming the quality of care for both our partners and our patients. Our partnerships are built upon four cornerstones for maximizing quality outcomes and financial performance: Growth, Profitability, Quality Outcomes & Satisfaction, Compliance. By utilizing a centralized operational model we`re able to deliver the highest level of efficiency to our partners. Our model is uniquely suited for success in at-risk and value-based reimbursement models with payers, hospitals and other providers.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling MAT9001 in a confirmatory head-to-head PK/PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in Q42020. In addition, the Company is developing MAT2203, an oral, encochleated formulation of Amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas` proprietary lipid nano-crystal (“LNC”) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.
Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.